Bisaro Paul 4

4 · Keenova Therapeutics plc · Filed Jan 5, 2026

Form 4

Period: 2026-01-01

Director

Transactions

Exercise/Conversion
Ordinary Shares
2026-01-01+3,014→ 5,032 total
Tax Payment
Ordinary Shares
2026-01-01−854→ 4,178 total
Disposition to Issuer
Restricted Stock Units
2026-01-01−2,466→ 46,255 total
→ Ordinary Shares (2,466 underlying)
Exercise/Conversion
Restricted Stock Units
2026-01-01−3,014→ 43,241 total
→ Ordinary Shares (3,014 underlying)

Footnotes (6)

[F1]Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
[F2]The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.
[F3]The Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person forfeited the right to receive 2,466 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the Reporting Person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest.
[F4]On February 19, 2024, the Reporting Person was granted 13,678 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below.
[F5]The number of RSUs forfeited is based on a percentage.
[F6]Reflects that the Reporting Person received 8,183 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.

Documents

1 file